In the recent National Institute for Health and Care Excellence (NICE) appraisals for rheumatoid arthritis, the six companies involved each independently conducted systematic reviews, economic modelling and network meta-analyses [1] . Each will have incurred substantial agency fees and internal time to manage the projects. Given the models were also based on a very similar structure, each needed to solve very similar problems (independently) from the perspective of disease progression. This is a typical situation, with examples ranging from psoriasis, chronic obstructive pulmonary disease, and multiple myeloma, with multiple companies creating almost identical models. In contrast, only a few examples exist of standardised models available to use by all (under varying frameworks [2, 3] )-diabetes is the only example that readily springs to mind [4] .
While this may be the norm for our industry [5] , we contend this does not represent a valuable use of scarce resources. Were companies to collaborate on modelling and evidence-generation activities, at the least at the disease level, there would be large benefits. These vary from improved modelling (reducing uncertainty), a broader evidence base, reduction of generating evidence that is duplicative or inconsistent, improved engagement with patients, lower costs and management time, additionally being ethically superior by making better use of patient input. We will discuss each of these areas in turn, as well as where collaboration is most likely to be advantageous.
Should a model be developed collaboratively by multiple companies, it would receive a much larger degree of scrutiny. While this may take longer to achieve a final version, it also means mistakes are less likely to survive the process. With multiple companies also collaborating on model design, the resulting model is also more likely to generalise to the condition (rather than only apply to one treatment); in that way, the model is more likely to become accepted in the eyes of payers, and set the standard for that disease area, a benefit to the companies involved.
Companies are also likely to be running trials in different stages of the disease; multiple myeloma is a good example, with some companies investigating first-line treatments, others second-line treatment, and others thirdline treatment and beyond. By pooling resources, there would be a broader evidence base, with companies able to ensure the inputs used from outside their own trial are robustly captured. The benefits here are twofold; first, in more reliable estimates of inputs and, second, in reduced cost of evidence generation (as this is shared)-this can be seen as a saving or used for further evidence generation.
By jointly developing a model, companies also have the potential to work with patient groups in a less transactional way. This can be used to get meaningful input, from the patient experience of the disease (and ensuring the model reflects this) to helping to populate health states (for example on working hours lost). While this is possible for individual companies, it is less straightforward. Rare diseases also only have a small pool of patients therefore a continuous stream of requests from different pharmaceutical companies may exhaust the goodwill of patients. Collecting data once (and comprehensively) in an effort to improve the modelling of the disease is preferable; such studies can then provide invaluable input to modellers and payers [6] .
The lower cost of collaboration should also be addressed. While a more complex and adaptable model may cost more to construct, this is likely to be by a percentage, and not a factor. As the cost will be divided by at least two companies, in all cases this will result in a cost saving, which increases as the number of collaborators increases. However, the true savings are much larger than they appear. For example, systematic reviews will only have to be completed once, with no extra cost to be delivered to multiple companies, while the internal time taken to manage contractors is a substantial element of the cost of modelling and would be reduced. With a contractor responsible for delivery to multiple companies, this element is shifted to the modelling agency (and explicitly costed in), rather than absorbed internally. This internal time can mean savings on staff time, or give time for other activities. The cost is then also borne by companies who have the greatest incentive to collect accurate data, rather than being contingent on a third party, as proposed by Afzali and Karnon [7] .
An additional factor that should be considered is the ethics of collaboration, something seldom relevant in health economics. When patients enter into clinical trials of novel treatments, they put their future health at risk to advance medical science. While complete data sharing between companies who may be competitors is not expected, the hard-earned data for patients receiving placebo treatment, for example, could be by multiple companies in their development programs. The sacrifice and risk taken by patients is therefore honoured and used for the benefit of the patient community.
In practical terms, the collaborative approach we propose at the company level is most likely to work in rare diseases and in conditions where there have been no developments for many years. In rare conditions, each company will be faced with the difficulty of understanding treatment pathways, and utilising scarce data to produce estimates-collaboration here is likely to help. Similarly, in disease areas that have not had developments for some time (for example in melanoma prior to ipilumumab and vemurafenib [8] ), similar problems apply as there is no best practice or established model, requiring a great deal of scoping and decision making. On the other hand, collaboration will be more difficult where companies are on radically different timelines, or are likely to be competing for a finite pool of identical patients (for example the myriad of treatments for advanced or metastatic nonsmall cell lung cancer).
While there are many benefits to collaboration, there are a number of issues to consider prior to companies entering into agreements. Briefly, we believe these to be the extent of data sharing, how the model should be maintained in the future, how costs should be shared (particularly if companies have different timelines or slightly different needs), and how the project should be managed. The legal implications of collaborating will also need to be carefully worded so as not to infringe rules on collusion (as price will be an input in models).
As a first step, Duchenne UK (a patient-led charity) are currently proposing a collaboration between companies developing products in Duchenne muscular dystrophy (a rare muscle-wasting disease affecting young boys). The disease pathway is complex, with current models not capturing important aspects of the condition and no data available for key inputs [9] . The goal of collaboration is to create a model that captures the entire disease pathway, including joint research on the natural history of disease, quality-of-life data from all clinical trials, and populated with other information collected from patient groups (for example on carer burden and out-of-pocket costs).
Ultimately, while collaboration is not suitable for every area, we find the status quo wasteful. The current situation squanders time and money (which must be covered by increased prices or lower returns), lowers quality (in turn increasing the chance of mistakes in resource allocation), increases uncertainty in modelling, and does not adequately respect the data generated from patients. When looking at upcoming projects, we urge companies to look beyond their own walls and see if there is a way to do more with less, improving outcomes for all.
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